3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Melanoma
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Lymphoma
1
Leukemia, Myeloid, Acute
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hematologic Neoplasms
1
Carcinoma, Merkel Cell
1
Interventions
pembrolizumab
6
Nivolumab
6
Ipilimumab
4
Radiotherapy
3
talimogene laherparepvec
2
budigalimab
2
avelumab
2
atezolizumab
2
Everolimus
2
Cyclophosphamide
2
zimberelimab
1
venetoclax
1
vatalanib
1
tremelimumab
1
temsirolimus
1
sapanisertib
1
rovalpituzumab tesirine
1
poly ICLC
1
oblimersen
1
lorvotuzumab mertansine
1
lanreotide
1
glucopyranosyl lipid-A
1
fludarabine
1
durvalumab
1
domatinostat
1
cixutumumab
1
cemiplimab
1
aldesleukin
1
Vinorelbine
1
Surgical Procedures, Operative
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Carcinoma, Merkel Cell
×
domatinostat
×
Clear all
NCT04393753
2024-05-08
MERKLIN2
4SC AG
Phase 2
Completed
19 enrolled